Paper Details

  1. Home
  2. Paper Details

The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.

Author: GuettnerA, HoegerP H, HultschT, JautovaJ, LeeK-H, MizutaniG, WohlrabJ

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Pimecrolimus cream 1% effectively controls eczema and pruritus in children with facial dermatitis intolerant of/dependent on topical corticosteroids and is well tolerated.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Atopic dermatitis (AD) is most prevalent in areas of reduced skin barrier reserve, like face and neck, especially in children. Treatment with topical corticosteroids (TCS) is limited due to heightened risk of treatment-associated side-effects, thus necessitating alternative AD therapies....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2133.2008.08928.x

データ提供：米国国立医学図書館（NLM）

A New Oasis for Facial Atopic Dermatitis: Pimecrolimus Cream 1%

[Facial atopic dermatitis (AD)] is a common skin condition that can cause significant discomfort and distress, much like a desert traveler experiencing a skin irritation from the harsh environment. This randomized controlled trial investigates the effectiveness of [pimecrolimus cream 1%] in treating facial AD in children who are intolerant or dependent on topical corticosteroids. The researchers compared the effects of pimecrolimus cream 1% to a vehicle placebo in a group of 200 children with facial AD.

Finding Relief in the Desert of Facial AD: Pimecrolimus Shows Promise

The results of this study are like discovering a refreshing oasis in the desert of facial AD. Pimecrolimus cream 1% proved to be an effective treatment option, demonstrating significant improvements in facial AD symptoms, including skin clearance, pruritus, and overall eczema severity. These findings suggest that pimecrolimus cream 1% could be a valuable alternative treatment for children with facial AD who cannot tolerate or are dependent on topical corticosteroids.

Navigating the Desert of Skin Conditions: Seeking New Solutions

This study, like a beacon of hope in the desert of skin conditions, highlights the importance of exploring new treatment options. The researchers emphasize the need for further research to investigate the long-term effects of pimecrolimus cream 1% and its potential benefits for other skin conditions, a journey that continues as we strive for better treatment options and improved quality of life for those struggling with skin disorders.

Dr. Camel's Conclusion

This research, like a desert oasis offering respite from the harsh sun, provides a promising new treatment option for children with facial AD. The findings suggest that pimecrolimus cream 1% could be a valuable alternative to topical corticosteroids, offering a potential path toward improved skin health and a more comfortable life for those affected.

Date :
  1. Date Completed 2009-04-13
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

19067708

DOI: Digital Object Identifier

10.1111/j.1365-2133.2008.08928.x

Related Literature

Article Analysis
・Side Effects of pimecrolimus topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.